Leerink analyst Faisal Khurshid downgraded Point Biopharma to Market Perform from Outperform with a price target of $12.50, up from $11, to reflect the Eli Lilly (LLY) acquisition price. Leerink sees the likelihood of a higher bid at this juncture as low, and views the acquisition as a positive for strategic interest in the radiopharma space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PNT:
- Eli Lilly (NYSE:LLY) Jumps on Analyst Optimism
- Point Biopharma downgraded to Market Perform from Outperform at Raymond James
- Point Biopharma downgraded to Hold from Buy at Truist
- Lantheus program validated by Point Biopharma buyout, says Mizuho
- Point Biopharma downgraded to Neutral from Buy at Guggenheim